Easier to produce COVID-19 vaccine shows promise in trials; Nasal spray vaccine booster works in mice

1/29/2022 4:20:00 AM

COVID-19 SCIENCE UPDATES Easier to produce COVID-19 vaccine shows promise in trials; Nasal spray vaccine booster works in mice

Covıd-19, Covıd Vaccine

COVID-19 SCIENCE UPDATES Easier to produce COVID-19 vaccine shows promise in trials; Nasal spray vaccine booster works in mice

A COVID-19 vaccine that can be produced locally in low- and middle-income countries is yielding promising results in early clinical trials, researchers say.Once the body has been "primed" by mRNA vaccines to recognize and attack the coronavirus, a booster containing purified versions of virus' spike protein that could be given intranasally would have many advantages, researchers believe.

PublishedJanuary 29, 2022 5:33amUsing blood samples from trial participants, researchers found that NDV-HXP-S induces proportionally more antibodies that can neutralize the virus and fewer non-neutralizing antibodies than the current mRNA vaccines from Moderna or Pfizer/BioNTech, they reported on Friday on medRxiv ahead of peer review.

The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.New COVID-19 vaccine could be manufactured like flu shotsA COVID-19 vaccine that can be produced locally in low- and middle-income countries is yielding promising results in early clinical trials, researchers say.

Read more: GMA News »

Lung transplants can help sickest COVID-19 survivorsPeople who need lung transplants as a result of COVID-19 do just as well afterward as those who get new lungs for other reasons, early data suggest.

Shayne Sava, ibinahagi na dalawang beses siyang nagpositibo sa COVID-19Ikinuwento ni Shayne Sava ang naging experience niya sa COVID-19 . Basahin DITO: I vote taylorswift13 for AllTooWell BestLyrics at the iHeartAwards!

DOH reports five deaths due to Covid-19 Omicron variant | Claudeth Mocon-CiriacoThe Department of Health (DOH) on Wednesday reported the death of five persons due to the Covid-19 Omicron variant. “As per verification, we have five recorded deaths,” Health Undersecretary Maria Rosario Vergeire said. Of the reported deaths, three are seniors and all have comorbidities. “One [was] partially vaccinated, one unvaccinated,…

Makati sends COVID-19 vaccines to BatangasThe Makati City local government sent 13,000 AstraZeneca vaccines to the province of Batangas on Wednesday, Jan. 26, as it continuously fight the surge in COVID-19 cases brought about by the more infectious Omicron and Delta variants.

Denmark to lift COVID-19 curbs in return to ‘life as we knew it’ADVERTISEMENT FEATURED STORIES NEWSINFO ‘I can’t take that sitting down!’ Sotto defends Lacson after Robredo comment NEWSINFO Lacson spurns Robredo’s ‘maraming salita, kulang sa gawa’ remark: ‘Hindi lang ako ma-epal’ NEWSINFO Robredo slams Bongbong, rivals in Boy Abunda’s interview COPENHAGEN — Denmark […]

Liam Payne postpones virtual show after contracting COVID-19Liam Payne has postponed his upcoming “Here’s To The Future” virtual showcase after testing positive for COVID-19 . | DCruzINQ

By NANCY LAPID, Reuters Published January 29, 2022 5:33am Using blood samples from trial participants, researchers found that NDV-HXP-S induces proportionally more antibodies that can neutralize the virus and fewer non-neutralizing antibodies than the current mRNA vaccines from Moderna or Pfizer/BioNTech, they reported on Friday on medRxiv ahead of peer review.The findings are reassuring, researchers say, because poor outcomes might rule out these patients' transplant eligibility even if their lungs were completely destroyed, given the shortage of available organs..The Department of Health (DOH) on Wednesday reported the death of five persons due to the Covid-19 Omicron variant.

The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review. New COVID-19 vaccine could be manufactured like flu shots A COVID-19 vaccine that can be produced locally in low- and middle-income countries is yielding promising results in early clinical trials, researchers say. The NDV-HXP-S vaccine, developed at Icahn School of Medicine at Mount Sinai in New York City, uses an engineered version of the harmless Newcastle disease virus studded with coronavirus spike proteins to teach the immune system to recognize and attack the virus that causes COVID-19. Using blood samples from trial participants, researchers found that NDV-HXP-S induces proportionally more antibodies that can neutralize the virus and fewer non-neutralizing antibodies than the current mRNA vaccines from Moderna or Pfizer/BioNTech, they reported on Friday on medRxiv ahead of peer review .1 and BA.

"The NDV-HXP-S vaccine induced neutralizing antibody responses against wild type (the original) SARS-CoV-2 that matched what we see after mRNA vaccination, but the proportion of neutralizing antibodies in the response was higher for NDV-HXP-S," said Mount Sinai's Florian Krammer. The vaccine can be manufactured like flu vaccines at low cost in chicken eggs at influenza vaccine manufacturing plants around the world, his team said. Early clinical trials with a live version are underway in Mexico and the United States, while an inactivated version is being tested in Vietnam, Thailand and Brazil, a spokesperson said. Mid-stage trials of the inactivated vaccine have also been completed and pivotal randomized trials are being planned. Intranasal booster uses virus spike to enhance immunity Once the body has been "primed" by mRNA vaccines to recognize and attack the coronavirus, a booster containing purified versions of virus' spike protein that could be given intranasally would have many advantages, researchers believe. According to Vergeire, BA.

Their "Prime and Spike" strategy employs a booster vaccine currently being tested in animals. In mice with waning immunity after two doses of the Pfizer/BioNTech shot, the purified spike protein vaccine strongly boosted first- and second-line immune responses to the virus in the nose, lungs and blood and protected against lethal doses of the virus, . Furthermore, the mice had lower-than-expected viral loads, which would likely reduce transmission. In mice whose immune systems had not been "primed" with the mRNA vaccine, the spike protein vaccine had no effect, however, because it takes advantage of the body's adaptive immunity, building on what the immune system has learned from the mRNA vaccine. "This strategy is likely to confer long-lasting and cross-reactive memory that can be quickly restimulated to prevent viral spread," study leader Akiko Iwasaki of Yale University explained on Twitter.1 and BA.

"The intranasal spike protein booster will also be much easier to administer (via nasal spray) ... and is much more likely to be accepted by people who are hesitant of mRNA or those with needle phobia." -- Reuters .2 sequences.